GlassScriptPhysician profile
Alessandra Haskin
NPI 1609302256
$3,207.98
in general payments reported to CMS, 2019-2025
20 companies · $2,457 in 2025
The $2,457 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $242 · 2022: $23.83 · 2023: $95.05 · 2024: $390 · 2025: $2,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,942.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $587.62 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $502.06 | 2024-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $394.06 | 2023-2025 | Zoryve |
| Abbvie INC. | $319.24 | 2021-2025 | |
| Viiv Healthcare Company | $176.86 | 2025 | Apretude |
| Leo Pharma INC. | $172.66 | 2025 | Anzupgo, Adbry |
| Genzyme Corporation | $153.43 | 2021-2024 | |
| Incyte Corporation | $129.55 | 2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $117.83 | 2021-2025 | |
| Lilly USA, LLC | $108.98 | 2025 | Taltz, Ebglyss |
| Sun Pharmaceutical Industries INC. | $97.45 | 2025 | |
| Journey Medical Corporation | $78.95 | 2023 | |
| Mayne Pharma Commercial LLC | $72.69 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $70.94 | 2025 | Siliq, Jublia, Cabtreo |
| Botanix Sb INC | $57.40 | 2025 | Sofdra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $47.62 | 2025 | Nemluvio |
| Amgen INC. | $44.99 | 2025 | Otezla |
| Vyne Pharmaceuticals INC. | $29.91 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.33 | 2021 | |
| Almirall LLC | $22.41 | 2025 | Seysara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alessandra Haskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.